Abstract

Background: The performance of Interferon gamma release assays (IGRA) in drug users and the impact of previous latent tuberculosis infection (LTBI) treatment on discordance of IGRA and tuberculin skin test (TST) are unclear. Objective: To determine the prevalence and incidence of LTBI using TST and Quantiferon Gold In-Tube test (QFT-G-IT) in a cohort of persons with hepatitis C virus (HCV) and drug use history. Design: Eligible participants had baseline TST and QFT-G-IT assay and were retested with QFT-G-IT after 12 months to assess prevalence and incidence of LTBI. Results: Of 193 HCV-infected persons enrolled, 162 (84%) were HIV infected; 132 (81%) were on anti-retroviral therapy and 131 (81%) had a CD4 count >200. 190 (98%) had a history of drug use; only 19 (10%) were active intravenous drug users. 55 (28.5%) had LTBI based on TST results and 13 (7%) were diagnosed with LTBI based on QFT-G-IT. 46/193 persons (23.8%) had positive TST with negative QFT-G-IT test. History of LTBI treatment was a strong predictor of this discordance (OR=41.5; 95%CI 16.2-106.7; p<0.0001). No QFT-G-IT conversions were detected among the 101 initially QFT-G-IT negative patients retested at one year (95% CI: 0-3.6%). Conclusions: Intravenous drug users who are not actively using drugs have a low prevalence and incidence of LTBI by IGRA. Previous LTBI treatment is associated with a positive TST and a concurrent negative QFT-G-IT.

Highlights

  • A third of the world’s population is infected with Latent Tuberculosis (LTBI) [1]

  • In the United States, the prevalence of latent tuberculosis infection (LTBI) in the general population is 4.2%, with higher percentages found in foreign-born persons, homeless individuals, prisoners, HIV patients, close contacts of persons with active tuberculosis and injection drug users [2,3]

  • 55/193 [28.5%, 95% CI 20.2%-39.5%] were found to have a positive tuberculin skin test and 138/193 had a negative test at baseline

Read more

Summary

Introduction

A third of the world’s population is infected with Latent Tuberculosis (LTBI) [1]. In the United States, the prevalence of LTBI in the general population is 4.2%, with higher percentages found in foreign-born persons, homeless individuals, prisoners, HIV patients, close contacts of persons with active tuberculosis and injection drug users [2,3]. Tuberculin skin testing (TST) has been the standard method for diagnosing LTBI for over 100 years. Interferon gamma release assays [IGRAs] have been introduced as an alternative method for detecting LTBI. The performance of Interferon gamma release assays (IGRA) in drug users and the impact of previous latent tuberculosis infection (LTBI) treatment on discordance of IGRA and tuberculin skin test (TST) are unclear

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call